129 related articles for article (PubMed ID: 7972979)
1. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Hansen NC; Skriver A; Brorsen-Riis L; Balsløv S; Evald T; Maltbaek N; Gunnersen G; Garsdal P; Sander P; Pedersen JZ
Respir Med; 1994 Aug; 88(7):531-5. PubMed ID: 7972979
[TBL] [Abstract][Full Text] [Related]
2. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Rasmussen JB; Glennow C
Eur Respir J; 1988 Apr; 1(4):351-5. PubMed ID: 3294038
[TBL] [Abstract][Full Text] [Related]
3. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
4. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Stey C; Steurer J; Bachmann S; Medici TC; Tramèr MR
Eur Respir J; 2000 Aug; 16(2):253-62. PubMed ID: 10968500
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials.
Grandjean EM; Berthet P; Ruffmann R; Leuenberger P
Clin Ther; 2000 Feb; 22(2):209-21. PubMed ID: 10743980
[TBL] [Abstract][Full Text] [Related]
6. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis.
Ekberg-Jansson A; Larson M; MacNee W; Tunek A; Wahlgren L; Wouters EF; Larsson S
Eur Respir J; 1999 Apr; 13(4):829-34. PubMed ID: 10362048
[TBL] [Abstract][Full Text] [Related]
7. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis.
Parr GD; Huitson A
Br J Dis Chest; 1987 Oct; 81(4):341-8. PubMed ID: 3329530
[TBL] [Abstract][Full Text] [Related]
8. [Steroid response after long-term treatment with oral N-acetylcysteine in patients with chronic obstructive bronchitis].
Evald T; Hansen M; Balsløv S; Brorson-Riis L; Hansen NC; Maltbaek N; Thorshauge H
Ugeskr Laeger; 1989 Nov; 151(46):2076-8. PubMed ID: 2688231
[TBL] [Abstract][Full Text] [Related]
9. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
Boman G; Bäcker U; Larsson S; Melander B; Wåhlander L
Eur J Respir Dis; 1983 Aug; 64(6):405-15. PubMed ID: 6350033
[TBL] [Abstract][Full Text] [Related]
10. [Multicenter, double-blind study of oral acetylcysteine vs. placebo].
Brocard H; Charpin J; Germouty J
Eur J Respir Dis Suppl; 1980; 111():65-9. PubMed ID: 7011834
[TBL] [Abstract][Full Text] [Related]
11. Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis.
Wei J; Pang CS; Han J; Yan H
Adv Ther; 2019 Dec; 36(12):3356-3367. PubMed ID: 31598901
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Zhang L; Xiong Y; Du L
Biomed Res Int; 2022; 2022():9133777. PubMed ID: 35795313
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis.
Grandjean EM; Berthet PH; Ruffmann R; Leuenberger P
Pharmacol Res; 2000 Jul; 42(1):39-50. PubMed ID: 10860633
[TBL] [Abstract][Full Text] [Related]
14. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study.
Dueholm M; Nielsen C; Thorshauge H; Evald T; Hansen NC; Madsen HD; Maltbaek N
Respir Med; 1992 Mar; 86(2):89-92. PubMed ID: 1615189
[TBL] [Abstract][Full Text] [Related]
15. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Beeh KM; Beier J; Candler H; Wittig T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis.
Grassi C; Morandini GC
Eur J Clin Pharmacol; 1976 Mar; 09(5-6):393-6. PubMed ID: 786665
[TBL] [Abstract][Full Text] [Related]
17. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
[TBL] [Abstract][Full Text] [Related]
18. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy?
Riise GC; Larsson S; Larsson P; Jeansson S; Andersson BA
Eur Respir J; 1994 Jan; 7(1):94-101. PubMed ID: 8143838
[TBL] [Abstract][Full Text] [Related]
19. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee.
Thorax; 1985 Nov; 40(11):832-5. PubMed ID: 2866607
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study.
Jackson IM; Barnes J; Cooksey P
J Int Med Res; 1984; 12(3):198-206. PubMed ID: 6376210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
